27.4 C
New York
Friday, August 29, 2025
HomeFinTechBotanix Pharmaceuticals: Passes FDA mid-cycle review for Sofpironium Bromide

Botanix Pharmaceuticals: Passes FDA mid-cycle review for Sofpironium Bromide

Botanix Pharmaceuticals Passes FDA mid-cycle review for Sofpironium Bromide

  • Botanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review
  • The FDA detected no safety issues and no risk management issues or board requirements in the review of the Botanix product
  • BOT says it will now continue discussions with the FDA around labelling, clinical outcome assessments, patient instructions and a brand name for its product
  • The planned approval date for Sofpironium Bromide remains on track for September 2023
  • BOT has called a trading halt ahead of a planned capital raise, and shares last traded at 10 cents
RELATED ARTICLES
- Advertisment -

Most Popular

Recent Comments